Um estudo randomizado controlado explorou a segurança e a tolerabilidade do sultiame na apneia do sono.

A Randomized Controlled Trial Exploring Safety and Tolerability of Sulthiame in Sleep Apnea – American Journal of Respiratory and Critical Care Medicine

Comunicado de imprensa: Drug reduced frequency of breathing pauses in sleep apnea – University of Gothenburg

Comentário no Twitter

In a four-week trial of patients with OSA not tolerating PAP therapy, researchers found that the carbonic anhydrase inhibitor sulthiame reduced OSA by more than 20 events per hour, one of the strongest reductions reported in a drug trial in OSA. https://t.co/EizlbFbvFm pic.twitter.com/DxylRQR4Pa

— American Academy of Sleep Medicine (@AASMorg) February 28, 2022